PERL - kidney biopsy

​(Tissue based integrative biology of diabetic kidney disease in participants of the PERL study).

Diabetic kidney disease (DKD) is a long-term complication to diabetes that continues to cause significant disease burden in type 1 diabetes (T1D) due to a poor understanding of its pathogenesis, as well as a paucity of non-invasive biomarkers, surrogate endpoints, and effective interventions. 

The PERL study examines if treatment leading to a lowering of uric acid levels in the blood in the form of the medicine Allopurinol, will have a protective effect in relation to the development of diabetic kidney disease. In the current study, a further characterization of participants in the PERL study is pursued, by a kidney biopsy to investigate mechanisms leading to diabetic kidney disease.

This study will provide the opportunity to combine tissue test results from the kidney with the extensive data collected in the PERL study.  It is the hypothesis of the PERL study that treatment leading to a lowering of uric acid levels in the blood will have a protective effect in relation to the development of diabetic kidney disease. It is the presumption that tissue samples in the form of kidney biopsy samples from participants in the PERL study will be able to strengthen the study by providing new information on which molecular mechanisms are driving this possible protective effect of the reduction of uric acid levels. We will potentially be able to find new ways of measuring kidney disease at an early stage in a non-invasive manner; e.g. blood or urine test. Similarly, new treatment methods could potentially be found. Data gathered in the context of this study will also provide a unique set of tissue-based disease profiles that other researchers will benefit from, thereby maximizing the utilization of the kidney biopsies.  

Aim

To investigate mechanisms leading to diabetic kidney disease.

Collaborators 

  • Ph.D-student Christina Gjerlev Poulsen
  • Consultant Thomas Elung-Jensen and Prof. Bo Feldt-Rasmussen, Dept. Of nephrology Nefrologisk Rigshospitalet, Copenhagen University.
  • Professors Markus Bitzer, Frank Brosius and Matthias Kretzler, University of Michigan
  • Prof. Michael Mauer, University of Minnesota






Responsible editor